Abstract
Oxymatrine (OMT), is a natural quinoxaline alkaloid from the traditional Chinese medicine herb and has been shown to exhibit anticancer properties on various types of cancer cells. Poorly differentiated gastric adenocarcinoma is a common malignancy of gastric cancer that is more aggressive and has a poor prognosis. In the present study, we investigate the effects of Slit2/Robo1 signals in poorly differentiated gastric adenocarcinoma and adjacent tissues, and the anticancer properties of OMT on human poorly differentiated gastric adenocarcinoma BGC-823 cells and evaluate their underlying mechanisms. The expression levels of Slit2 and Robo1 proteins were measured in 20 pairs of human poorly differentiated gastric adenocarcinoma tissues and adjacent normal tissues using western blot. The expression of apoptosis related proteins and autophagy-related proteins was detected by western blot. The cells viability was detected by CCK-8 assay. The migration of BGC-823 cells was detected by transwell experiments. The expression of related proteins was detected by western blot. The result shows that Slit2 and Robo1 are significantly increased in poorly differentiated gastric adenocarcinoma. The apoptosis and autophagy are inhibited in poorly differentiated gastric adenocarcinoma. OMT inhibits the growth and migration of BGC-823 cells in vitro. OMT inhibits the activation of Slit2/Robo1 signals and induces apoptosis and autophagy in BGC-823 cells. These findings suggest that the antitumor effects of OMT may be the result of inhibition of cell growth and migration, and inhibits the activation of Slit2/Robo1 signals pathway and induces apoptosis and autophagy. OMT may represent a novel anticancer therapy for the treatment of poorly differentiated gastric adenocarcinoma.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Natural Science Foundation of Ningxia Hui Autonomous Region to Li-qiong Ma (NZ17172), the Ningxia Medical University Research Fund to Li-qiong Ma (XM2016030). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was approved by the ethics committee of General Hospital of Ningxia Medical University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data, models, and code generated or used during the study appear in the submitted article.
